ALC
Neutral signalScored 2026-10-06 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Alcon Inc.
- Nom
- Alcon Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Specialties
- Bourse
- NYSE
- Capitalisation
- $33.9B
- Employés
- 25,000
- PDG
- David J. Endicott
- Site web
- https://www.alcon.com
- Marché
- BLCOCOOESLOYGKOSHOCPFIRIX
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-08-05 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2026-03-12 | Josh S. Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2025-03-03 | Julie Johnson | Sale | $1,001 - $15,000 |
| 2024-06-21 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-07-10 | Daniel Goldman | Sale (Full) | $15,001 - $50,000 |
| 2022-02-17 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-02-17 | Peter Meijer | Sale (Full) | $15,001 - $50,000 |
| 2020-10-16 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-09-15 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-06-05 | Greg Gianforte | Purchase | $100,001 - $250,000 |
| 2020-06-03 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-06-02 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2019-11-01 | Debbie Dingell | Purchase | $1,001 - $15,000 |
| 2019-04-15 | Alan Lowenthal | Sale (Full) | $15,001 - $50,000 |
| 2019-04-15 | Alan Lowenthal | Sale (Full) | $15,001 - $50,000 |
| 2019-04-15 | Alan Lowenthal | Sale (Full) | $1,001 - $15,000 |
| 2019-04-11 | Debbie Dingell | Exchange | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
ALC presents a balanced profile with solid liquidity (75) anchored by low leverage and improving long-term margins, offset by softening near-term profitability and a moderate catalyst score (55).
The first sentence of the analysis written for ALC on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 2.12 · operating margin 13%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 55.2% | 55.6% | 55.5% | 54.5% | 56.1% | |
| Ebit Margin | 11.2% | 14.6% | 10.8% | 7.1% | 6.5% | |
| Ebitda Margin | 22.6% | 27.0% | 23.7% | 20.4% | 21.2% | |
| Operating Profit Margin | 13.1% | 14.3% | 11.0% | 7.7% | 7.0% | |
| Pretax Profit Margin | 11.2% | 12.7% | 8.8% | 5.3% | 5.0% | |
| Continuous Operations Profit Margin | 9.4% | 10.3% | 10.3% | 3.8% | 4.5% | |
| Net Profit Margin | 9.4% | 10.3% | 10.3% | 3.8% | 4.5% | |
| Bottom Line Profit Margin | 9.4% | 10.3% | 10.3% | 3.8% | 4.5% | |
| Current Ratio | 2.115 | 2.770 | 2.355 | 1.897 | 2.179 | |
| Quick Ratio | 1.331 | 1.774 | 1.387 | 1.126 | 1.411 | |
| Solvency Ratio | 0.228 | 0.255 | 0.244 | 0.157 | 0.183 | |
| Cash Ratio | 0.501 | 0.736 | 0.456 | 0.358 | 0.637 | |
| Price To Earnings Ratio | 39.603 | 41.209 | 39.455 | 100.809 | 113.143 | |
| Price To Earnings Growth Ratio | -11.655 | 10.199 | 0.206 | -8.625 | -0.663 | |
| Forward Price To Earnings Growth Ratio | -11.655 | 10.199 | 0.206 | -8.625 | -0.663 | |
| Price To Earnings Diluted Ratio | 39.803 | 41.410 | 39.857 | 100.809 | 114.632 | |
| Price To Earnings Diluted Growth Ratio | -11.657 | 9.018 | 0.212 | -9.577 | -0.675 | |
| Price To Book Ratio | 1.770 | 1.947 | 1.867 | 1.712 | 2.217 | |
| Price To Sales Ratio | 3.750 | 4.235 | 4.073 | 3.864 | 5.149 | |
| Price To Free Cash Flow Ratio | 24.258 | 29.829 | 71.719 | 71.368 | 258.720 | |
| Price To Operating Cash Flow Ratio | 17.176 | 20.207 | 27.747 | 27.679 | 31.739 | |
| Debt To Assets Ratio | 0.166 | 0.169 | 0.173 | 0.174 | 0.160 | |
| Debt To Equity Ratio | 0.238 | 0.238 | 0.249 | 0.258 | 0.233 | |
| Debt To Capital Ratio | 0.192 | 0.192 | 0.199 | 0.205 | 0.189 | |
| Long Term Debt To Capital Ratio | 0.159 | 0.174 | 0.185 | 0.188 | 0.171 | |
| Financial Leverage Ratio | 1.432 | 1.408 | 1.436 | 1.484 | 1.454 | |
| Working Capital Turnover Ratio | 2.799 | 2.723 | 3.315 | 3.247 | 2.939 | |
| Operating Cash Flow Ratio | 0.745 | 0.912 | 0.579 | 0.444 | 0.544 | |
| Operating Cash Flow Sales Ratio | 0.218 | 0.210 | 0.147 | 0.140 | 0.162 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.708 | 0.677 | 0.387 | 0.388 | 0.123 | |
| Debt Service Coverage Ratio | 2.787 | 8.489 | 10.059 | 7.003 | 7.563 | |
| Interest Coverage Ratio | 6.667 | 7.589 | 5.497 | 4.856 | 4.823 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.950 | 20.564 | 28.917 | 12.546 | 12.570 | |
| Operating Cash Flow Coverage Ratio | 0.433 | 0.404 | 0.270 | 0.240 | 0.300 | |
| Capital Expenditure Coverage Ratio | 3.425 | 3.100 | 1.631 | 1.634 | 1.140 | |
| Dividend Paid And Capex Coverage Ratio | 2.739 | 2.596 | 1.435 | 1.435 | 1.090 | |
| Dividend Payout Ratio | 0.169 | 0.128 | 0.119 | 0.308 | 0.144 | |
| Enterprise Value Multiple | 18.174 | 16.977 | 18.980 | 21.264 | 25.894 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 55.2% | ▼-0.4% | ▼-0.1% |
| Ebit Margin | 11.2% | ▼-3.5% | ▲1.1% |
| Ebitda Margin | 22.6% | ▼-4.4% | ▼-0.4% |
| Operating Profit Margin | 13.1% | ▼-1.2% | ▲2.5% |
| Pretax Profit Margin | 11.2% | ▼-1.5% | ▲2.6% |
| Continuous Operations Profit Margin | 9.4% | ▼-0.9% | ▲1.8% |
| Net Profit Margin | 9.4% | ▼-0.9% | ▲1.8% |
| Bottom Line Profit Margin | 9.4% | ▼-0.9% | ▲1.8% |
| Current Ratio | 2.115 | ▼-0.654 | ▼-0.148 |
| Quick Ratio | 1.331 | ▼-0.443 | ▼-0.075 |
| Solvency Ratio | 0.228 | ▼-0.027 | ▲0.015 |
| Cash Ratio | 0.501 | ▼-0.235 | ▼-0.037 |
| Price To Earnings Ratio | 39.603 | ▼-1.606 | ▼-27.241 |
| Price To Earnings Growth Ratio | -11.655 | ▼-21.854 | ▼-9.547 |
| Forward Price To Earnings Growth Ratio | -11.655 | ▼-21.854 | ▼-9.547 |
| Price To Earnings Diluted Ratio | 39.803 | ▼-1.607 | ▼-27.499 |
| Price To Earnings Diluted Growth Ratio | -11.657 | ▼-20.675 | ▼-9.121 |
| Price To Book Ratio | 1.770 | ▼-0.177 | ▼-0.133 |
| Price To Sales Ratio | 3.750 | ▼-0.484 | ▼-0.464 |
| Price To Free Cash Flow Ratio | 24.258 | ▼-5.571 | ▼-66.921 |
| Price To Operating Cash Flow Ratio | 17.176 | ▼-3.031 | ▼-7.734 |
| Debt To Assets Ratio | 0.166 | ▼-0.003 | ▼-0.002 |
| Debt To Equity Ratio | 0.238 | ▼-0.000 | ▼-0.005 |
| Debt To Capital Ratio | 0.192 | ▼-0.000 | ▼-0.003 |
| Long Term Debt To Capital Ratio | 0.159 | ▼-0.015 | ▼-0.016 |
| Financial Leverage Ratio | 1.432 | ▲0.024 | ▼-0.011 |
| Working Capital Turnover Ratio | 2.799 | ▲0.077 | ▼-0.205 |
| Operating Cash Flow Ratio | 0.745 | ▼-0.167 | ▲0.100 |
| Operating Cash Flow Sales Ratio | 0.218 | ▲0.009 | ▲0.043 |
| Free Cash Flow Operating Cash Flow Ratio | 0.708 | ▲0.031 | ▲0.252 |
| Debt Service Coverage Ratio | 2.787 | ▼-5.702 | ▼-4.393 |
| Interest Coverage Ratio | 6.667 | ▼-0.923 | ▲0.780 |
| Short Term Operating Cash Flow Coverage Ratio | 3.950 | ▼-16.615 | ▼-11.760 |
| Operating Cash Flow Coverage Ratio | 0.433 | ▲0.029 | ▲0.103 |
| Capital Expenditure Coverage Ratio | 3.425 | ▲0.325 | ▲1.239 |
| Dividend Paid And Capex Coverage Ratio | 2.739 | ▲0.143 | ▲0.880 |
| Dividend Payout Ratio | 0.169 | ▲0.042 | ▼-0.004 |
| Enterprise Value Multiple | 18.174 | ▲1.197 | ▼-2.084 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $39.01B | $41.97B | $38.51B | $33.69B | $42.69B | |
| Enterprise value | $42.73B | $45.43B | $42.55B | $37.77B | $45.59B | |
| EV / Sales | 4.11x | 4.58x | 4.50x | 4.33x | 5.50x | |
| EV / Op. cash flow | 18.81x | 21.87x | 30.66x | 31.04x | 33.90x | |
| EV / Free cash flow | 26.57x | 32.29x | 79.24x | 80.03x | 276.32x | |
| EV / EBITDA | 18.17x | 16.98x | 18.98x | 21.26x | 25.89x | |
| Net debt / EBITDA | 1.58x | 1.29x | 1.80x | 2.30x | 1.65x | |
| Current ratio | 2.12x | 2.77x | 2.35x | 1.90x | 2.18x | |
| Income quality | 2.32x | 2.04x | 1.43x | 3.63x | 3.58x | |
| Graham number | $45 | $45 | $43 | $25 | $26 | |
| Graham net-net | -$11 | -$9 | -$11 | -$12 | -$10 | |
| Tax burden | 84.5% | 81.1% | 117.1% | 72.4% | 90.0% | |
| Interest burden | 100.0% | 86.7% | 81.5% | 75.1% | 77.5% | |
| Working capital | $3.40B | $4.03B | $3.25B | $2.46B | $2.91B | |
| Invested capital | $26.88B | $26.40B | $25.96B | $25.53B | $24.67B | |
| Return on assets | 3.1% | 3.4% | 3.3% | 1.1% | 1.3% | |
| Operating ROA | 4.4% | 4.7% | 3.5% | 2.3% | 2.1% | |
| Return on tangible assets | 7.4% | 7.9% | 8.4% | 3.2% | 3.6% | |
| Return on equity | 4.4% | 4.7% | 4.7% | 1.7% | 2.0% | |
| Return on invested capital | 3.9% | 4.1% | 3.8% | 1.8% | 2.0% | |
| Return on capital employed | 4.8% | 5.0% | 3.8% | 2.5% | 2.3% | |
| Earnings yield | 2.5% | 2.4% | 2.5% | 1.0% | 0.9% | |
| Free cash flow yield | 4.1% | 3.4% | 1.4% | 1.4% | 0.4% | |
| Capex / Op. cash flow | 29.2% | 32.3% | 61.3% | 61.2% | 87.7% | |
| Capex / Depreciation | 49.7% | 54.6% | 69.7% | 66.3% | 96.8% | |
| Capex / Sales | 6.4% | 6.8% | 9.0% | 8.5% | 14.2% | |
| SG&A / Sales | 33.2% | 32.8% | 33.9% | 35.2% | 37.1% | |
| R&D / Sales | 9.5% | 8.8% | 9.1% | 8.1% | 10.2% | |
| Stock comp / Sales | 1.6% | 1.5% | 1.5% | 1.6% | 1.7% | |
| Intangibles / Total assets | 57.9% | 57.8% | 60.7% | 63.9% | 63.1% | |
| Days sales outstanding | 68d | 77d | 73d | 83d | 70d | |
| Days payables outstanding | 73d | 64d | 70d | 79d | 91d | |
| Operating cycle | 256d | 265d | 274d | 277d | 261d | |
| Cash conversion cycle | 183d | 201d | 204d | 198d | 170d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-04 Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now? Alcon''s acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.
- 2026-09-03 Alcon: A Re-Rating In Eyesight Alcon is a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. At $72, ALC trades at ~18x forward earnings, reflecting mid-teens EPS growth but pricing in neither margin expansion nor pipeline optionality. Management targets 25% core operating margin by FY2027E, with current core EPS guidance raised to +12–15% growth and significant capital returns underway.
- 2026-09-03 Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control GENEVA--(BUSINESS WIRE)--Alcon Launches UNITY® M, a Premium Ophthalmic Microscope Delivering Precise Control.
- 2026-08-26 Alcon Prices EUR 500 Million Senior Notes Offering GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500 Million Senior Notes Offering.
- 2026-08-17 Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy Alcon reported strong core operating profit (barring a one-time non-cash $402 million charge) during the quarter, up 17%. The company raised its full-year 2026 profit forecast for the second consecutive quarter. My DCF valuation states the stock is undervalued by 5.52%. I rate ALC a buy.
- 2026-08-14 Bill Ackman Just Disclosed 6 New Positions, and 4 of Them Are Financial Stocks. Here''s What He''s Betting On. The famous long-term investor and his team made notable changes to Pershing Square''s equity portfolio.
- 2026-08-13 Why Netflix Stock Popped Today Bill Ackman (Trades, Portfolio)''s Pershing Square Capital Management has built a new position in Netflix (NFLX), returning to the streaming company after a cost
- 2026-08-13 Bill Ackman Buys Back Into Netflix Four Years After Selling at a Loss Bill Ackman (Trades, Portfolio) disclosed six new holdings, buying Netflix (NFLX), Visa (V), Mastercard (MA), eye care company Alcon (ALC), exchange operator In
- 2026-08-13 Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.
- 2026-08-11 Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript